Enzychem Lifesciences Corp

Chart & Performance

D1W1MN

P/E

—

P/S

1.24

EPS

—

Div Yield, %

—

Shrs. gr., 5y

6.72%

Rev. gr., 5y

21.28%

Revenues

67.75b

-12.44%

Net income

-18.13b

L-17.98%

CFO

-11.01b

L+1,818.74%

Dividend

Mar 15, 20221.71 KRW/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Enzychem Lifesciences Corporation, a pharmaceutical company, primarily dedicates itself to formulating oral, small-molecule therapies aimed at addressing urgent unmet medical needs for patients in South Korea suffering from conditions in oncology, metabolic diseases, and inflammatory disorders. Furthermore, the firm is actively developing innovative treatments utilizing its EC-18 technology platform to combat chemotherapy-induced neutropenia, oral mucositis triggered by chemoradiation therapy, and acute radiation syndrome. Founded in 1999, its headquarters are situated in Seoul, South Korea.

URL

http://www.enzychem.co.kr/

IPO date

Sep 25, 2013

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT